vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Falcon's Beyond Global, Inc. (FBYD). Click either name above to swap in a different company.
Arbutus Biopharma Corp is the larger business by last-quarter revenue ($10.7M vs $6.6M, roughly 1.6× Falcon's Beyond Global, Inc.). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs -4.5%, a 28.0% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 383.5%). Over the past eight quarters, Falcon's Beyond Global, Inc.'s revenue compounded faster (108.4% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
500 Global is an early-stage venture fund and seed accelerator founded in 2010 by Dave McClure and Christine Tsai. The fund admitted a first "class" of twelve startups to its incubator office in Mountain View, California in February 2011. They expanded to a second class of 21 in June 2011 and a third class of 34 in October 2011. 500 Global has $2.3 billion in assets under management (AUM) as of March 2024.
ABUS vs FBYD — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $6.6M |
| Net Profit | $2.5M | $-296.0K |
| Gross Margin | — | — |
| Operating Margin | 13.9% | -30.9% |
| Net Margin | 23.5% | -4.5% |
| Revenue YoY | 522.2% | 383.5% |
| Net Profit YoY | 112.7% | 97.5% |
| EPS (diluted) | $0.01 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $6.6M | ||
| Q3 25 | — | $4.1M | ||
| Q2 25 | $10.7M | $2.5M | ||
| Q1 25 | — | $1.7M | ||
| Q4 24 | — | $1.4M | ||
| Q3 24 | — | $2.1M | ||
| Q2 24 | — | $1.8M | ||
| Q1 24 | — | $1.5M |
| Q4 25 | — | $-296.0K | ||
| Q3 25 | — | $-10.4M | ||
| Q2 25 | $2.5M | $25.1M | ||
| Q1 25 | — | $-8.1M | ||
| Q4 24 | — | $-11.9M | ||
| Q3 24 | — | $39.3M | ||
| Q2 24 | — | $8.0M | ||
| Q1 24 | — | $114.0M |
| Q4 25 | — | -30.9% | ||
| Q3 25 | — | -90.9% | ||
| Q2 25 | 13.9% | -53.0% | ||
| Q1 25 | — | -371.1% | ||
| Q4 24 | — | -335.6% | ||
| Q3 24 | — | -118.9% | ||
| Q2 24 | — | -195.9% | ||
| Q1 24 | — | -350.5% |
| Q4 25 | — | -4.5% | ||
| Q3 25 | — | -256.8% | ||
| Q2 25 | 23.5% | 985.2% | ||
| Q1 25 | — | -473.8% | ||
| Q4 24 | — | -871.7% | ||
| Q3 24 | — | 1899.5% | ||
| Q2 24 | — | 446.5% | ||
| Q1 24 | — | 7521.4% |
| Q4 25 | — | $-0.01 | ||
| Q3 25 | — | $-0.13 | ||
| Q2 25 | $0.01 | $0.30 | ||
| Q1 25 | — | $-0.13 | ||
| Q4 24 | — | $-0.25 | ||
| Q3 24 | — | $0.39 | ||
| Q2 24 | — | $0.00 | ||
| Q1 24 | — | $1.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $1.9M |
| Total DebtLower is stronger | $0 | $15.6M |
| Stockholders' EquityBook value | $83.0M | $11.9M |
| Total Assets | $103.3M | $66.7M |
| Debt / EquityLower = less leverage | 0.00× | 1.31× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.9M | ||
| Q3 25 | — | $4.3M | ||
| Q2 25 | $37.4M | $26.1M | ||
| Q1 25 | — | $1.1M | ||
| Q4 24 | — | $825.0K | ||
| Q3 24 | — | $828.0K | ||
| Q2 24 | — | $1.7M | ||
| Q1 24 | — | $1.1M |
| Q4 25 | — | $15.6M | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $41.2M | ||
| Q3 24 | — | $10.3M | ||
| Q2 24 | — | $15.7M | ||
| Q1 24 | — | $15.1M |
| Q4 25 | — | $11.9M | ||
| Q3 25 | — | $9.2M | ||
| Q2 25 | $83.0M | $414.0K | ||
| Q1 25 | — | $-11.6M | ||
| Q4 24 | — | $-9.0M | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | — | $-44.7M | ||
| Q1 24 | — | $-61.7M |
| Q4 25 | — | $66.7M | ||
| Q3 25 | — | $66.8M | ||
| Q2 25 | $103.3M | $89.2M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $61.2M | ||
| Q3 24 | — | $66.5M | ||
| Q2 24 | — | $65.9M | ||
| Q1 24 | — | $67.8M |
| Q4 25 | — | 1.31× | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $-4.3M |
| Free Cash FlowOCF − Capex | — | $-4.3M |
| FCF MarginFCF / Revenue | — | -66.0% |
| Capex IntensityCapex / Revenue | 0.0% | 0.3% |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-4.3M | ||
| Q3 25 | — | $-13.3M | ||
| Q2 25 | $-15.7M | $-7.9M | ||
| Q1 25 | — | $945.0K | ||
| Q4 24 | — | $-3.8M | ||
| Q3 24 | — | $-2.4M | ||
| Q2 24 | — | $-2.6M | ||
| Q1 24 | — | $-3.8M |
| Q4 25 | — | $-4.3M | ||
| Q3 25 | — | $-13.4M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $853.0K | ||
| Q4 24 | — | $-3.8M | ||
| Q3 24 | — | $-2.4M | ||
| Q2 24 | — | $-2.6M | ||
| Q1 24 | — | $-3.8M |
| Q4 25 | — | -66.0% | ||
| Q3 25 | — | -329.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 49.9% | ||
| Q4 24 | — | -278.7% | ||
| Q3 24 | — | -114.9% | ||
| Q2 24 | — | -145.6% | ||
| Q1 24 | — | -248.8% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 1.0% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | — | 5.4% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | -0.31× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -0.06× | ||
| Q2 24 | — | -0.33× | ||
| Q1 24 | — | -0.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
